GEN News Highlights

Diabetes research organization JDRF and Becton, Dickinson and Company (BD) have extended their existing type 1 diabetes collaboration to include further development of the latter’s next-generation continuous glucose-sensing platform. The technology is relevant to JDRF’s partnership with the Helmsley Charitable Trust (HCT), which aims to develop artificial pancreas systems that comprise continuous glucose measurement sensors to enable automatic delivery of the right amount of insulin.

“Combined with our existing JDRF collaboration to develop microneedle insulin infusion, this latest collaboration with JDRF and The Helmsley Charitable Trust demonstrates the parties’ commitment to further improving the patient experience and enabling the artificial pancreas,” states Linda Tharby, president for diabetes care at BD Medical.

Back in 2010 BD and JDRF established a collaboration focused on the development of products that deliver insulin from a pump to a patient in either an infusion set or patch-pump configuration. The research program was one of the first nonexclusive industry initiatives undertaken by JDRF as part of its Artificial Pancreas Project, which ultimately aims to speed the development of fully automated diabetes management systems.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.1%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.